Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
ZYME Stock Chart & Stats
$23.47
-$0.11(-0.77%)
At close: 4:00 PM EST
$23.47
-$0.11(-0.77%)
Day’s Range― - ―
52-Week Range$9.03 - $28.49
Previous CloseN/A
Volume35.38K
Average Volume (3M)784.62K
Market Cap
$1.77B
Enterprise Value$1.06B
Total Cash (Recent Filing)$251.93M
Total Debt (Recent Filing)$18.90M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Mar 11, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding74,836,530
10 Day Avg. Volume1,288,237
30 Day Avg. Volume784,619
Financial Highlights & Ratios
PEG Ratio1.56
Price to Book (P/B)3.28
Price to Sales (P/S)14.55
P/FCF Ratio-9.82
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue7.89
Enterprise Value/Gross Profit7.89
Enterprise Value/Ebitda-19.67
Forecast
1Y Price Target
$35.55Price Target Upside51.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)0.57
Revenue Forecast (FY)$254.37M
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyAnalyst notes that Phase 3 HERIZON-GEA demonstrated clinically meaningful improvements in progression-free and overall survival versus the control regimen, positioning zanidatamab as a likely new HER2 treatment option for relevant gastric and esophageal cancers.
Regulatory And Commercial MilestonesAnalyst highlights that Zymeworks is eligible for substantial regulatory and commercial milestone payments and tiered royalties from partner agreements, which could materially boost recurring revenue if approvals and launches progress as expected.
Strategic Business Model ShiftAnalyst points out that the pivot to a royalty-driven model and planned reinvestment of upfront and milestone proceeds into royalty purchases, targeted acquisitions, and selective R&D could generate higher-margin, more durable cash flows compared with the legacy biotech approach.
Bears Say
Financial And Execution RiskAnalyst highlights high cash burn and a constrained cash runway combined with investor skepticism about the strategic shift, which could pressure the stock if milestone timing or royalty deal execution falls short of expectations.
Safety And TolerabilityAnalyst cautions that somewhat higher rates of serious adverse events with the zanidatamab combination versus the comparator may limit physician adoption and complicate commercial uptake without effective mitigation strategies.
Uncertain Survival BenefitAnalyst warns that overall survival results favored zanidatamab but failed to reach statistical significance, creating uncertainty around a clear long-term survival advantage and potential implications for market positioning.
Zymeworks News
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $9.03 and its highest was $28.49 in the past 12 months.
What is Zymeworks Inc’s market cap?
Zymeworks Inc’s market cap is $1.77B.
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Mar 11, 2026 which is in 52 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Nov 06, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.295 by $0.035.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -0.47.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 74,836,530 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.295. Following the earnings report the stock price went down -8.045%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Currently, no hedge funds are holding shares in ZYME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.55 (51.45% Upside)
$35.55 (51.45% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 624.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.76%
12-Months-Change
Fundamentals
Return on Equity
-18.46%
Trailing 12-Months
Asset Growth
-18.45%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of strong revenue growth and promising clinical data that suggest a positive outlook for Zymeworks. However, the discontinuation of a key program and the decrease in cash reserves present challenges. The sentiment is largely buoyed by the revenue increase and positive clinical trial results.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$35.55
▲(51.45% Upside)
Technical Analysis
Arcus Biosciences
―
Replimune Group
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---